An announcement from Oncimmune Holdings ( (GB:ONC) ) is now available.
Oncimmune Holdings plc has announced a strategic update following a recent decline in its share price, highlighting efforts to seek strategic partnerships and additional financing. The company has appointed Alvarez & Marsal to pursue potential partners and investors, while engaging in discussions for fundraising to extend its cash runway beyond April 2025. Despite current financial challenges, Oncimmune remains optimistic about its long-term prospects, with ongoing projects and significant potential contracts that could materially impact its financial performance.
More about Oncimmune Holdings
Oncimmune Holdings plc is a precision medicine company that specializes in analyzing immune interactions through autoantibody profiling. The company partners with global pharmaceutical and biotech companies, as well as contract research organizations, to discover novel biomarkers for developing targeted and effective therapies across various immune-mediated diseases. Headquartered in the UK, with facilities in Germany and teams in the US and Europe, Oncimmune aims to enable precision medicine by deploying its scientific team and technology platform.
YTD Price Performance: -82.72%
Average Trading Volume: 315,109
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £2.77M
Find detailed analytics on ONC stock on TipRanks’ Stock Analysis page.